An interventional study of CS-101 in Beta-Thalassemia, sponsored by Children's Hospital of Fudan University. Recruiting at 1 site in China. Open to participants aged 3 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-10-26.
Sponsored by Children's Hospital of Fudan University · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 44 studies in beta-Thalassemia with a site in China — 20 open to participants now, 25 under way, 1 of them phase 3. beta-Thalassemia · China.
Among the 44 studies in beta-Thalassemia with a site in China, this one is the 23rd largest by planned enrollment of the 34 interventional ones that give a count, is one of 11 that started in 2024, is one of 13 with no phase, reaches primary completion later than 10 of the 24 other live ones, and was the 37th registered.
295 studies on the registry are indexed under beta-Thalassemia; 70 are open to participants now.
Browse beta-Thalassemia studies →20 of the 44 studies in beta-Thalassemia with a site in China are open now. Recruiting first, the newest first:
Mabwell (Shanghai) Bioscience Co., Ltd. · Sites in China
Ages 18–65
Bioray Laboratories · Sites in China
Ages 3–35
Guangzhou Women and Children's Medical Center · Sites in China
Ages 7–10
Kanglin Biotechnology (Hangzhou) Co., Ltd. · Sites in China
Ages 3–35
Shanghai BDgene Co., Ltd. · Sites in China
Ages 6–35
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 43 beta-Thalassemia studies recruiting now, 10 (23%) set no upper age limit and 31 (72%) stop at 75 or younger; 34 take children under 18; 6 take healthy volunteers.
This study: 3 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
44 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 8 · Phase 3 1 · Phase 4 4
First in 2012; this study’s year is marked. 11 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 5 is below the median of 40 across 209 interventional studies indexed under beta-Thalassemia.
Median enrollment 10 across the 34 interventional studies, 96 across the 10 observational. Of the 11 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 44 have an industry lead sponsor. The 10 most frequent:
Children's Hospital of Fudan University is the lead sponsor of 268 studies on the registry; 94 are open to participants now.
Children's Hospital of Fudan University has 2 studies filed under beta-Thalassemia — fewer than ten, so there is no comparison to draw.
4 of the studies in beta-Thalassemia with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06479616Children's Hospital of Fudan UniversityA Long-term Follow-up Study in Participants Who Received CS-101 | 2026-12 |
| NCT06308159Lantu BiopharmaAn Open-label Study of a Gene Therapy Product (Vebeglogene Autotemcel) in Transfusion Dependent Beta-Thalassemia | 2027-08-01 |
| NCT05860595Institute of Hematology & Blood Diseases Hospital, ChinaEvaluation the Safety and Efficacy of KL003 Cell Injection in the Treatment of Transfusion-dependent β-thalassemia. | 2027-08-20 |
| NCT06280378Kanglin Biotechnology (Hangzhou) Co., Ltd.β-Thalassemia Treatment With KL003 Cell Injection | 2027-11-20 |
Add all 4 to your calendar (.ics) → With an account.
Among the 44 studies in beta-Thalassemia with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a study to evaluate the long-term safety and efficacy of CS-101 in participants who received CS-101 in study CS -101-03 (NCT06065189)
This is a study to evaluate the long-term safety and efficacy of CS-101 in participants who received CS-101 in study CS -101-03 (NCT06065189) .
Subjects in the CS-101-03 study will be entered into long-term follow-up of this study up to 2 years post-infusion at the completion of the last (6-month) follow-up visit after treatment with CS-101 Injection.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All participants who complete CS-101-03(NCT0606518) studie after CS-101 infusion will be asked to participate in this long-term follow-up study.
Genetic: CS-101
Autologous CD34+ hematopoietic stem cell suspension modified by in vitro base editing technique
Frequency and severity of SAEs and CS-101 related AES as assessed by CTCAE v5.0
CommonTerminology Criteria for Adverse Events(CTCAE)has 5 levels of AE determination, increasing in severity as the level increases
Time frame: Signing of informed consent up to 2 years post CS-101 infusion
Occurrence of all-cause death
Time frame: Signing of informed consent up to 2 years post CS-101 infusion
New malignancies and hematologic disorders
Based on ICD-11
Time frame: Signing of informed consent up to 2 years post CS-101 infusion
Occurrence of achieving transfusion independence for at least 12 consecutive months
Time frame: From 3 months after last RBC transfusion up to 2 years post CS-101 infusion
Change in fetal hemoglobin(HbF) concentration over time
Time frame: up to 2 years post-CS-101 infusion
Change in total hemoglobin(Hb) concentration over time
Time frame: up to 2 years post-CS-101 infusion
Chimerism level in Peripheral blood and bone marrow Proportion of alleles with intended genetic modification in peripheral blood leukocytes and bone marrow over time
Proportion of alleles with intended genetic modification in peripheral blood leukocytes and bone marrow over time
Time frame: up to 2 years post-CS-101 infusion
Started Jun 2024 (actual). Primary completion is estimated for Dec 2026, 30 months after the start.
Of 29 interventional studies with no phase under beta-Thalassemia, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 69. This study's planned 30 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Children's Hospital of Fudan University →